Drug Trial Radar · NCT06367283
Metformin Treatment of Patients with Hand Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 3, 2024
Primary completion
Dec 2025
Study completion Apr 2026
Sponsor
- Lead sponsor
- Marius HenriksenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare metformin (2 g daily), or maximum tolerated dose, for 16 weeks with placebo as a treatment of hand osteoarthritis symptoms.
Conditions
- Hand Osteoarthritis
Interventions
MetforminDrug
Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
PlaceboDrug
Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Finger painTime frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Parker Institute, Bispebjerg and Frederiksberg hospital
Copenhagen, Frederiksberg, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.